Document Type

Article

Embargo Period

8-1-1975

Publication Date

8-1-1975

Abstract

Adult murine hosts undergoing induction and regression of primary Moloney sarcoma virus (MSV) tumors develop antibodies (1-3) and lymphocytes (4-6) which have activity in vitro against Moloney leukemia virus (MLV)-determined cell surface antigens on the tumor target cells (7). Antibodies which are able to lyse the appropriate virus-induced tumor target cells in the presence of complement appear in two peaks with respect to time after MSV injection (1). The first peak occurs in the early tumor-bearing animals 10-15 days after MSV (1). This is followed by a drop in the antibody titers in early regressors whereafter the antibodies rise and maintain high titers in long-term regressor animals (1, 8). The early as well as the late peaks contained cytotoxic activity in both the IgG and IgM fractions (1). Such MLC-specific antibodies are also active in the induction of tumor cell destruction in vitro by normal lymphoid cells (8). We have recently reported that both IgG and IgM were able to induce cytotoxicity by nonimmune spleen cells as well as potentiate the cytotoxic activity of immune spleen cells (9). We now report that IgM from MSV regressor mice will induce cytotoxicity against the tumor target cells not only by normal spleen cells but by normal thymocytes and the thymus cell cytotoxicity in combination with IgM appears to be more efficient than that produced with spleen cells.

Journal

Journal of Experimental Medicine

Download

Share

COinS